Lilly
Eli Lilly and Company
- HQ
- United States
- Status
- active
- Listing
- Listed · LLY
- Current stage
- commercial
- Key people
- Carole Ho (EVP and president, Lilly Neuroscience)
sec.govregistryverified 2026-09-15
Notes on the record
Acquirer in D001-lilly-ataibeckley-2026. Separately the sponsor of the brenipatide programme (A006), which is not part of that acquisition. Supersedes the row verified 2026-08-25. Merger closed 2026-09-11; AtaiBeckley Inc. is a wholly owned subsidiary. No Lilly 8-K on the closing as of 2026-09-15 (submissions API HTTP 200; the only September filing is a Form 4 for an unrelated 2025 transaction). Sponsor of record on six brenipatide CTIS records (A006), the sixth in asthma.
Assets
Phase 3 in MDD (two pivotals) and alcohol use disorder (two pivotals); Phase 2 in bipolar disorder, IBS-D, IBS-C and asthma (CTIS 2025-522640-41-00, 52-week, authorised DE and FR 2026-01-21, PL 2026-01-30, NL 2026-02-02; recruitment started PL 2026-02-18) · major depressive disorder; alcohol use disorder; bipolar disorder; irritable bowel syndrome (IBS-D, IBS-C); uncontrolled moderate to severe asthma
euclinicaltrials.euregistryverified 2026-09-15
Registered trials
PHASE2 · Bipolar Disorder · RECRUITING · Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States
clinicaltrials.govctgov registryverified 2026-08-31
PHASE3 · Depressive Disorder, Major · RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-08-31
PHASE3 · Depressive Disorder, Major · NOT_YET_RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-08-31
Therapeutic confirmatory (Phase III) · Depressive Disorder, Major · Authorised · Germany, Greece, Poland, Spain
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany
euclinicaltrials.euctis registryverified 2026-09-15
Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome Diarrhea · Authorised · Belgium, Germany, Poland, Spain
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome - Constipation · Authorised · Belgium, Spain
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Uncontrolled moderate to severe asthma · Authorised · Germany, France, Netherlands, Poland
euclinicaltrials.euctis registryverified 2026-09-15
Deals
Eli Lilly and Company acquires AtaiBeckley Inc.
acquisition · closed · $3800m headline
sec.govsec filingverified 2026-09-25
In the briefing
5 issues tagged LILLY.